> Detailanzeige

Massari, Francesco; Santoni, Matteo; Takeshita, Hideki; Okada, Yohei; Tapia, Jose Carlos; Basso, Umberto; Maruzzo, Marco; Scagliarini, Sarah; Büttner, Thomas; Fornarini, Giuseppe; Myint, Zin W.; Galli, Luca; Souza, Vinicius Carrera; Pichler, Renate; De Giorgi, Ugo; Gandur, Nathalia; Lam, Elaine T.; Gilbert, Danielle; Popovic, Lazar; Grande, Enrique; Mammone, Giulia; Berardi, Rossana; Crabb, Simon J.; Kemp, Robert; [...]

Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study
  • Beteiligte: Massari, Francesco; Santoni, Matteo; Takeshita, Hideki; Okada, Yohei; Tapia, Jose Carlos; Basso, Umberto; Maruzzo, Marco; Scagliarini, Sarah; Büttner, Thomas; Fornarini, Giuseppe; Myint, Zin W.; Galli, Luca; Souza, Vinicius Carrera; Pichler, Renate; De Giorgi, Ugo; Gandur, Nathalia; Lam, Elaine T.; Gilbert, Danielle; Popovic, Lazar; Grande, Enrique; Mammone, Giulia; Berardi, Rossana; Crabb, Simon J.; Kemp, Robert; [...]
  • Erschienen: Springer Science and Business Media LLC, 2024
  • Erschienen in: Cancer Immunology, Immunotherapy
  • Sprache: Englisch
  • DOI: 10.1007/s00262-024-03682-w
  • ISSN: 1432-0851
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:title>Abstract</jats:title><jats:sec> <jats:title>Background</jats:title> <jats:p>Immune checkpoint inhibitors have changed previous treatment paradigm of advanced urothelial carcinoma (UC). The ARON-2 study (NCT05290038) aimed to assess the real-world effectiveness of pembrolizumab in patients recurred or progressed after platinum-based chemotherapy.</jats:p> </jats:sec><jats:sec> <jats:title>Patients and Methods</jats:title> <jats:p>Medical records of patients with documented metastatic UC treated by pembrolizumab as second-line therapy were retrospectively collected from 88 institutions in 23 countries. Patients were assessed for overall survival (OS), progression-free survival (PFS) and overall response rate (ORR). Cox proportional hazards models were adopted to explore the presence of prognostic factors.</jats:p> </jats:sec><jats:sec> <jats:title>Results</jats:title> <jats:p>In total, 836 patients were included: 544 patients (65%) received pembrolizumab after progression to first-line platinum-based chemotherapy in the metastatic setting (cohort A) and 292 (35%) after recurring within &lt; 12 months since the completion of adjuvant or neoadjuvant chemotherapy (cohort B). The median follow-up time was 15.3 months. The median OS and the ORR were 10.5 months and 31% in the overall study population, 9.1 months and 29% in cohort A and 14.6 months and 37% in cohort B. At multivariate analysis, ECOG-PS ≥ 2, bone metastases, liver metastases and pembrolizumab setting (cohort A vs B) proved to be significantly associated with worst OS and PFS. Stratified by the presence of 0, 1–2 or 3–4 prognostic factors, the median OS was 29.4, 12.5 and 4.1 months (<jats:italic>p</jats:italic> &lt; 0.001), while the median PFS was 12.2, 6.4 and 2.8 months, respectively (<jats:italic>p</jats:italic> &lt; 0.001).</jats:p> </jats:sec><jats:sec> <jats:title>Conclusions</jats:title> <jats:p>Our study confirms that pembrolizumab is effective in the advanced UC real-world context, showing outcome differences between patients recurred or progressed after platinum-based chemotherapy.</jats:p> </jats:sec>
  • Zugangsstatus: Freier Zugang